Vol 43, Issue 1

Therapeutic drug monitoring revolutionizes psychiatric care, enhancing treatment precision and patient outcomes through real-time data and personalized medicine strategies.

In this CME article, explore the groundbreaking role of muscarinic cholinergic receptors in schizophrenia treatment, highlighting innovative therapies like KarXT for improved patient outcomes.

Exploring the vital link between nutrition and mental health, this article highlights dietary strategies to enhance psychiatric well-being and cognitive function.

Explore how lifestyle psychiatry transforms depression treatment through nutrition, exercise, sleep, and social connections for holistic recovery and resilience.

Explore the emerging role of lifestyle interventions in psychiatry, enhancing patient care through nutrition and physical activity for mental health.

Innovative combinations of transcranial magnetic stimulation and ketamine therapy offer new hope for treatment-resistant depression, pain, and substance use disorders.

Explore groundbreaking insights from the 2025 Southern Florida Psychiatry Conference, covering VNS for depression, stuttering management, and postpartum care.

"I’m idling on the parking garage roof..."

Research reveals that reducing anticholinergic burden can significantly enhance cognitive function in patients with psychosis, offering new treatment insights.

Emergency departments face challenges in detecting suicidality among trauma patients, highlighting the need for effective screening and intervention strategies.

Psychiatric Times is excited to embrace change with new digital editions and engaging content, and invite you, our readers, to explore diverse topics across multiple platforms.

Psychiatric Times embraces innovation with interactive digital issues and a new print format, enhancing accessibility for psychiatric clinicians.

Psychiatric Times is adapting to the evolving media landscape, focusing on impactful stories and insights, starting with schizophrenia and lifestyle psychiatry.

Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.